Allena Pharmaceuticals
ALNA
ALNA was delisted on the 7th of September, 2022.
30 hedge funds and large institutions have $10.1M invested in Allena Pharmaceuticals in 2021 Q4 according to their latest regulatory filings, with 4 funds opening new positions, 7 increasing their positions, 8 reducing their positions, and 9 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
13% less repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 8
17% less funds holding
Funds holding: 36 → 30 (-6)
44% less capital invested
Capital invested by funds: $18M → $10.1M (-$7.9M)
56% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 9
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1M |
| 2 |
VF
Virtu Financial
New York
|
+$105K |
| 3 |
KAS
Kestra Advisory Services
Austin,
Texas
|
+$44.2K |
| 4 |
SWM
Spire Wealth Management
Mclean,
Virginia
|
+$32.8K |
| 5 |
LFAS
Level Four Advisory Services
Dallas,
Texas
|
+$31.3K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FM
Frazier Management
Seattle,
Washington
|
-$1.31M |
| 2 |
ACM
Altium Capital Management
New York
|
-$963K |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$822K |
| 4 |
GCP
GSA Capital Partners
London,
United Kingdom
|
-$138K |
| 5 |
Renaissance Technologies
New York
|
-$120K |
ALNA Hedge Fund Activity: Q4 2021 in Review
30 of the 6,499 institutional investors tracked by Wall St. Rank reported a position in Allena Pharmaceuticals (ALNA) for Q4 2021, worth a combined $10.1M — down 44% from $18M a quarter earlier.
Sellers outnumbered buyers: 9 funds closed out of ALNA and 4 opened new positions — a net loss of 5 holders — while 8 trimmed existing stakes and 7 added.
The largest buyer was Vanguard Group, adding an estimated $1M. The largest seller was Frazier Management, cutting an estimated $1.31M.
- 30 institutional investors held Allena Pharmaceuticals (ALNA) as of Q4 2021, down from 36 in Q3 2021.
- Funds reported $10.1M of Allena Pharmaceuticals stock for Q4 2021, down 44% quarter-over-quarter.
- 4 funds opened new Allena Pharmaceuticals positions in Q4 2021 and 9 closed out, a net change of -5 holders.
- The largest Allena Pharmaceuticals buyer in Q4 2021 was Vanguard Group, an estimated $1M added.
- The largest Allena Pharmaceuticals seller in Q4 2021 was Frazier Management, an estimated $1.31M sold.
Based on aggregated 13F filings for Q4 2021.